153 related articles for article (PubMed ID: 38368730)
1. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study.
Meng H; Lam SH; So H; Tam LS
Semin Arthritis Rheum; 2024 Apr; 65():152416. PubMed ID: 38368730
[TBL] [Abstract][Full Text] [Related]
2. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis.
Cooksey R; Brophy S; Kennedy J; Gutierrez FF; Pickles T; Davies R; Piguet V; Choy E
Semin Arthritis Rheum; 2018 Dec; 48(3):367-373. PubMed ID: 29656791
[TBL] [Abstract][Full Text] [Related]
4. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.
Ogdie A; Yu Y; Haynes K; Love TJ; Maliha S; Jiang Y; Troxel AB; Hennessy S; Kimmel SE; Margolis DJ; Choi H; Mehta NN; Gelfand JM
Ann Rheum Dis; 2015 Feb; 74(2):326-32. PubMed ID: 25351522
[TBL] [Abstract][Full Text] [Related]
5. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.
So H; Lam TO; Meng H; Lam SHM; Tam LS
Ann Rheum Dis; 2023 Nov; 82(11):1387-1393. PubMed ID: 37487608
[TBL] [Abstract][Full Text] [Related]
6. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis.
Lauper K; Courvoisier DS; Chevallier P; Finckh A; Gabay C
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1756-1763. PubMed ID: 29609199
[TBL] [Abstract][Full Text] [Related]
8. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
9. Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Patients With Psoriatic Arthritis Compared to Patients Without Psoriatic Arthritis.
Li L; Hagberg KW; Peng M; Shah K; Paris M; Jick S
J Clin Rheumatol; 2015 Dec; 21(8):405-10. PubMed ID: 26406567
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study.
Jafri K; Bartels CM; Shin D; Gelfand JM; Ogdie A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):51-57. PubMed ID: 27696731
[TBL] [Abstract][Full Text] [Related]
11. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
Sparks JA; Lesperance T; Accortt NA; Solomon DH
Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
[TBL] [Abstract][Full Text] [Related]
12. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
13. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study.
Gelfand JM; Wan J; Zhang H; Shin DB; Ogdie A; Syed MN; Egeberg A
J Am Acad Dermatol; 2021 Jun; 84(6):1636-1643. PubMed ID: 33607181
[TBL] [Abstract][Full Text] [Related]
14. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study.
Dubreuil M; Rho YH; Man A; Zhu Y; Zhang Y; Love TJ; Ogdie A; Gelfand JM; Choi HK
Rheumatology (Oxford); 2014 Feb; 53(2):346-52. PubMed ID: 24185762
[TBL] [Abstract][Full Text] [Related]
15. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis.
Solomon DH; Love TJ; Canning C; Schneeweiss S
Ann Rheum Dis; 2010 Dec; 69(12):2114-7. PubMed ID: 20584807
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study.
Lindström U; di Giuseppe D; Exarchou S; Alenius GM; Olofsson T; Klingberg E; Jacobsson L; Askling J; Wallman JK
RMD Open; 2023 May; 9(2):. PubMed ID: 37173095
[TBL] [Abstract][Full Text] [Related]
17. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Colebatch AN; Marks JL; Edwards CJ
Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
[TBL] [Abstract][Full Text] [Related]
18. Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study.
Jin Y; Chen SK; Liu J; Kim SC
Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1248-1256. PubMed ID: 32754989
[TBL] [Abstract][Full Text] [Related]
19. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
Christensen IE; Lillegraven S; Mielnik P; Bakland G; Loli L; Sexton J; Uhlig T; Kvien TK; Provan SA
Ann Rheum Dis; 2022 Mar; 81(3):398-401. PubMed ID: 34625404
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
